tbuckley/cabot-search huggingface dataset:
Minimal Residual Disease (MRD) in Adult T-Cell Leukemia/Lymphoma (ATLL) Evaluated by HTLV-1 Proviral Load and Soluble IL-2 Receptor Level in Peripheral Blood.
Authors: Kunihiro Tsukasaki, Shigeki Takemoto, Hirokuni Taguchi, Masato Masuda, Syuichi Ikeda, Shinichiro Yoshida, Hitoshi Suzushima, Naokuni Uike, Yoshio Saburi, Fumio Kawano, Masaomi Yamamura, Eizaburo Sueoka, Masaharu Miyahara, Masao Tomonaga
Journal: Blood (2005)
Applying the Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI) in Myeloablative MUD Transplants Predicts NRM and OS Using a Modified 2-Tier Scoring System.
Authors: Tibor Kovacsovics, Byung Park, Brandon Hayes-Lattin, Jose F. Leis, Peter T. Curtin, Gabrielle Meyers, Elliot Epner, Richard T. Maziarz
Journal: Blood (2007)
ACTR-57. TEXTILOMA-AN UNUSUAL MIMIC OF BRAIN TUMOR RECURRENCE: A CASE SERIES
Authors: Deborah Forst, Derek Oakley, Tracy Batchelor, Jorg Dietrich
Journal: Neuro-Oncology (2016)

To report a single-institution series of five cases of post-operative intracranial textiloma formation mimicking tumor recurrence or progression. Textiloma is a rare enhancing mass lesion caused by an inflammatory reaction to retained foreign material following surgery. This may be a response to a larger retained object such as a surgical sponge or gauze, or from a robust reaction to microscopic cotton or rayon fibers, or other synthetic hemostatic agents. Textiloma formation has been reported as an acute post-operative surgical complication, or may occur months to years after surgery. More commonly described after intra-abdominal surgeries, there are only a few anecdotal reports of spinal or intracranial textiloma in the literature. Retrospective analysis of imaging and clinical features in 5 patients with textiloma. We identified 5 patients (age from 29 to 54 years; median 30 years) with underlying glioma (n=4) and glioneuronal tumor (n=1). In all five cases, brain MRI demonstrated a peripherally enhancing lesion, commonly with restricted diffusion, which was identified 1 day to 4 years after surgery. 4/5 patients were asymptomatic. Biopsy or surgical excision was obtained in 4 cases, confirming an extensive giant cell reaction to foreign material, including birefringent fibers consistent with cotton, and non-polarizable material consistent with a synthetic hemostatic material. In all cases, diagnosis of textiloma directly affected treatment, often sparing the patient from unnecessary therapies initially intended for tumor progression. Intracranial textiloma is a rare intracranial mass lesion mimicking recurrent tumor and resulting from an inflammatory reaction to retained foreign material following a surgical procedure. Lesions may occur acutely or develop months to years after surgery. While considered rare, textiloma is an important consideration in the differential diagnosis of a progressive tumor, in light of indistinguishable MRI imaging characteristics.
Oncogenic Effects of High MAPK Activity in Colorectal Cancer Mark Progenitor Cells and Persist Irrespective of RAS Mutations
Authors: Cristina Blaj, Eva Marina Schmidt, Sebastian Lamprecht, Heiko Hermeking, Andreas Jung, Thomas Kirchner, David Horst
Journal: Cancer Research (2017)

Abstract About 40% of colorectal cancers have mutations in KRAS accompanied by downstream activation of MAPK signaling, which promotes tumor invasion and progression. Here, we report that MAPK signaling shows strong intratumoral heterogeneity and unexpectedly remains regulated in colorectal cancer irrespective of KRAS mutation status. Using primary colorectal cancer tissues, xenograft models, and MAPK reporter constructs, we showed that tumor cells with high MAPK activity resided specifically at the leading tumor edge, ceased to proliferate, underwent epithelial–mesenchymal transition (EMT), and expressed markers related to colon cancer stem cells. In KRAS-mutant colon cancer, regulation of MAPK signaling was preserved through remaining wild-type RAS isoforms. Moreover, using a lineage tracing strategy, we provide evidence that high MAPK activity marked a progenitor cell compartment of growth-fueling colon cancer cells in vivo. Our results imply that differential MAPK signaling balances EMT, cancer stem cell potential, and tumor growth in colorectal cancer. Cancer Res; 77(7); 1763–74. ©2017 AACR.
NIMG-50. FIRST REPORT OF USER EXPERIENCE, COMPLIANCE OUTCOMES, AND ALARM STATES WITH THE SECOND GENERATION OPTUNE® SYSTEM
Authors: Adrian Kinzel, Mike Ambrogi, Michael Varshaver, Laura Benson, Eilon Kirson
Journal: Neuro-Oncology (2016)

Tumor Treating Fields (TTFields) are an established, non-invasive anti mitotic therapy delivered via the Optune System which is approved in the United States, Europe, and Australia for the treatment of adult patients with newly diagnosed and recurrent supratentorial glioblastoma (GBM). TTFields are delivered through 4 transducer arrays that are placed directly on the scalp to target the tumor. The original Optune system consisting of a field generator, portable lithium batteries, dedicated carrying bag, and transducer arrays weighs about 6 pounds. The system has been redesigned to improve the convenience and manageability of TTFields therapy for patients. The second generation Optune System, uses novel digital signal generation technology to reduce the size and weight to 2.7 pounds (1.3 kilograms) including the battery. To understand the impact of the updated system on patient satisfaction, compliance (time on therapy), and usability, ten GBM patients in Germany (N=10, male=8, female=2, median age: 52.9 years [31-79]) were monitored at multiple time points over the first month of transitioning to the second generation Optune System. A numerical analog scale was utilized to assess feedback at baseline (on the original system) and at 5 specific time points over the first month of second generation Optune System usage. Patient feedback highlighted the benefits of enhanced features such as quieter operation and portability. Overall, patients were very satisfied with the new system and experienced a fewer number of alarms. It is well established that target compliance rates of 75% (18 hours per day) improve survival outcomes in GBM studies. Patient compliance using the second generation Optune System was maintained and in most cases improved compared to the compliance rates observed with the original Optune device.
Antagonists to Retinoid Receptors Down-Regulate CD38 Expression and Inhibit In Vitro Differentiation of Cord Blood Derived CD34+ Cells.
Authors: Tony Peled, Ela Glukhman, Sophie Adi, Efrat Landau, Nira Hasson, Chana Lador, Julie Mandel, Eitan Fibach
Journal: Blood (2006)
Endothelial antigen assembly leads to thrombotic complications in heparin-induced thrombocytopenia
Authors: Vincent Hayes, Ian Johnston, Gowthami M. Arepally, Steven E. McKenzie, Douglas B. Cines, Lubica Rauova, Mortimer Poncz
Journal: Journal of Clinical Investigation (2017)

Heparin-induced thrombocytopenia (HIT) is a prothrombotic disorder initiated by antibodies against complexes between human platelet factor 4 (hPF4) and heparin. A better understanding of the events that initiate the prothrombotic state may improve approaches to antithrombotic management. Here, we visualized thrombus formation in an in vivo murine model and an endothelialized microfluidic system that simulate the pathogenesis of HIT. hPF4 released from platelets predominantly bound to peri-injury endothelium and formed HIT antigenic complexes that were dissociated by heparin. In mice expressing both hPF4+ and human platelet IgG Fc receptor IIA (FcγRIIA), infusion of the HIT-like monoclonal antibody KKO increased fibrin and platelet deposition at sites of injury, followed immediately by antigen formation on proximate endothelial cells. After a few minutes, HIT antigen was detected within the thrombus itself at the interface between the platelet core and the surrounding shell. We observed similar results in the humanized, endothelialized microfluidic system. hPF4 and KKO selectively bound to photochemically injured endothelium at sites where surface glycocalyx was reduced. These studies support the concept that the perithrombus endothelium is the predominant site of HIT antigen assembly. This suggests that disrupting antigen formation along the endothelium or protecting the endothelium may provide a therapeutic opportunity to prevent thrombotic complications of HIT, while sparing systemic hemostatic pathways.
Biotin-Induced Biochemical Graves Disease
Authors: Anu Sharma, Nikola A. Baumann, Pankaj Shah
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Eliglustat, an Investigational Oral Therapy for Gaucher Disease Type 1: Phase 2 Results After 4 Years of Treatment
Authors: M. Judith Peterschmitt, Elena Lukina, Nora Watman, Marta Dragosky, Gregory M Pastores, Elsa Avila Arreguin, Hanna Rosenbaum, Ari Zimran, Elena Sysoeva, Rasha Aguzzi, Leorah H Ross, Ana Cristina Puga
Journal: Blood (2012)
Prognostic significance of neutrophil to lymphocyte ratio (NLR) in patients (pts) with resectable gastric/gastroesophageal junction (GOJ) adenocarcinoma undergoing perioperative chemotherapy
Authors: Z. Salih, A.M. Conway, G. Papaxoinis, A. Patrao, K. Fletcher, R. Noble, V. Owen-Holt, W. Mansoor
Journal: Annals of Oncology (2016)
Continuing to deliver: the evidence base for pre-implantation genetic screening
Authors: Darren K Griffin, Simon Fishel, Tony Gordon, Yuval Yaron, Jamie Grifo, Ariel Hourvitz, Svetlana Rechitsky, Janine Elson, Joshua Blazek, Francesco Fiorentino, Nathan Treff, Santiago Munne, Milton Leong, Andreas Schmutzler, Attila Vereczkey, Tarek Ghobara, László Nánássy, Michael Large, Samir Hamamah, Robert Anderson, Luca Gianaroli, Dagan Wells
Journal: BMJ (2017)

We respond to the comments made in the BBC commissioned article by Heneghan and colleagues and the Panorama programme by Deborah Cohen about pre-implantation genetic screening (PGS), which was among the three “add on” treatments highlighted in the programme and the 41 listed in the article.12 Currently an extensive evidence base supports the efficacy of PGS: more than 20 retrospective studies and four randomised controlled trials suggest that, if performed to a high standard, PGS can, and does, improve IVF success for some patient groups.34567 We accept, however, that all studies are open to criticism and thus support further investigations, randomised and retrospective. However, the programme, …
Multigene expression profile for predicting efficacy of cisplatin and vinorelbine in non-small cell lung cancer
Authors: I.K. Buhl, I.J. Christensen, E. Santoni-Rugiu, J. Ravn, A. Hansen, T. Jensen, J. Askaa, P.B. Jensen, S. Knudsen, J.B. Soerensen
Journal: Annals of Oncology (2016)
Clinical and molecular analysis of long-term HER2 positive metastatic breast cancer survivors
Authors: C. Omarini, C. Caprera, S. Manfredini, F. Caggia, G. Guaitoli, M.E. Filieri, S.R. Bettelli, L. Moscetti, S. Kaleci, A.V. Tamma, S. Cascinu, F. Piacentini
Journal: Annals of Oncology (2016)
Personalized medicine for advanced pancreas cancer: access to treatment according to molecular profile
Authors: C. Romeo, P. Cassier, A.l.a. De Fouchardière, D. Pissaloux, V. Attignon, Q. Wang, M. Sarabi, F. Desseigne, P. Guibert, D. Perol, O. Tredan, J.-Y. Blay, Cdela Fouchardiere
Journal: Annals of Oncology (2016)
Long-Term Effects of In Vivo Administration of An Anti-VLA-4 Antibody (natalizumab) on Mobilization of Committed and Primitive Hematopoietic Progenitor Cells In Humans
Authors: Jorge Domenech, Julien Goustille, Maud Pallix, Zakia Bekhechi, Elfi Ducrocq, Michel Degenne, Olivier Herault, Gilles Thibault, Anne-Marie Guennoc, Christian Binet
Journal: Blood (2010)
Signal transducer and activator of transcription–3 (STAT3) expression concordance in paired primary and metastatic colorectal cancers (mCRC)
Authors: D. Yokom, S. Sud, H. Marginean, T. Asmis, D.J. Jonker, G. Martel, A. Gown, M. Daneshmand, E.C. Marginean, R. Goodwin
Journal: Annals of Oncology (2016)
Pembrolizumab in patients with Bacillus Calmette Guérin (BCG)-unresponsive, high-risk non–muscle-invasive bladder cancer (NMIBC): Phase 2 KEYNOTE-057 study
Authors: R. de Wit, A.M. Kamat, J. Bellmunt, T.K. Choueiri, K. Nam, M. De Santis, R. Dreicer, N.M. Hahn, R. Perini, A.O. Siefker-Radtke, G. Sonpavde, J.A. Witjes, S. Keefe, D. Bajorin
Journal: Annals of Oncology (2016)
A Two-Site Interaction Underpins TRIM25 Activation of the RIG-I Anti-Viral Response
Authors: Akshay A D'Cruz, Nadia J Kershaw, Edmond M Linossi, Jessica J Chiang, May K Wang, Laura F Dagley, Ben A Croker, Jian-Guo Zhang, Michaela U Gack, Nicos A Nicola, Jeffrey J Babon, Sandra E Nicholson
Journal: Blood (2014)
GENT-18. DIFFERENTIAL BRD4-BOUND STRETCH/SUPER ENHANCERS DRIVE CRITICAL SEX DIFFERENCES IN GBM PHENOTYPE
Authors: Najla Kfoury, Zongtai Qi, Kristopher Berrett, Albert Kim, Jason Gertz, Robi Mitra, Joshua Rubin
Journal: Neuro-Oncology (2016)

Significant sex differences in GBM demands understanding at a molecular level. RNA sequencing of a well-characterized murine model of sex differences in mesenchymal glioblastoma (mes-GBM) revealed significant sex differences in the expression of multiple transcription factors, signaling molecules and regulators of metabolism. We hypothesized that these differences in gene expression represented a cellular sex identity that would be driven by differential usage of Brd4-bound stretch/super-enhancers (SE). These recently described genetic elements are characterized by disproportionate binding of the transcription factors Med1 and Brd4 and their occupancy, or usage, drives high levels of expression of lineage- and cell- state specific genes, including those required for malignant transformation. We utilized transposon “calling cards” to map active Brd4 binding sites genome-wide. We found reproducible differences in SE occupancy by Brd4 in male and female mes-GBM cells. Sex differences in occupancy were validated using histone ChIP-PCR for the SE-associated histone marks, H3K27Ac and H3K4me3. The functional significance of sex-specific SE usage was determined by treating male and female mes-GBM cells with the Brd4 antagonist JQ1. Treatment with JQ1 reproducibly abrogated the basal differences in stem-like cell frequency between male and female mes-GBM cells resulting in a decreased functional stem cell fraction in male cells and an increased functional stem cell fraction in female cells. Sex-specific effects of JQ1 were evident in vitro as well as in in vivo tumorigenesis assays. These data establish for the first time that cellular sex-identity is driven by differential SE usage and that sex differences in SE usage accounts for critical sex differences in GBM phenotype. These data have significant implications for the clinical applications of JQ1.
MPTH-07. ROLE OF CELL-CYCLE REGULATORS IN PREDICTING PROGRESSION OF SILENT PITUITARY ADENOMA AFTER SURGICAL RESECTION
Authors: Sung Hyun Park, Ji Hwan Jang
Journal: Neuro-Oncology (2016)

This study investigated the use of cell-cycle regulators for predicting progression of silent pituitary adenoma (SPA) after surgical resection via immunohistochemical analysis of tumor samples obtained by surgical resection. We reviewed the medical records of patients diagnosed with SPA from January 2000 to December 2013 in our institute. Immunohistochemical staining was performed on sections of the archived, paraffin-embedded tissues obtained by surgery; cell-cycle regulatory proteins p16, p15, p21, CDK 4 and 6, pRB protein, and cyclin D1; MIB-1 antigen; and p53. The primary end-point was to investigate the expression of cell-cycle regulatory proteins in SPA. The secondary end-point was to estimate the progression-free survival of SPA after surgical resection and find out its association with the expression of cell-cycle regulatory protein. Of the 127 SPA samples, 44 (34.6%) were from patients with progression during a mean follow-up period of 62.4 months (range 24.2–118.9 months). Immunohistochemistry (IHC) was reactive in 61 samples (48.0%) for p16, in 38 samples (29.9%) for p15, in 19 samples (15.0%) for p21, in 49 samples (38.6%) for CDK4, in 17 samples (13.4%) for CDK6, in 57 samples (44.9%) for pRB protein, and in 65 samples (51.2%) for cyclin D1. Multivariate analysis using a Cox proportional hazard regression model showed that null cell adenoma (95% confidence interval [CI] 0.276–0.808); somatotroph SPAs (95% CI, 1.296–3.121); corticotroph SPAs (95% CI 1.811–4.078); pluripotent SPAs (95% CI 2.264–5.194); immunohistochemical normostaining for p16 (95% CI 2.724–5.588); immunohistochemical overstaining for pRB protein (95% CI 2.557–5.333), cyclin D1 (95% CI 1.894–4.122), or MIB-1 (95% CI 1.561–4.133); mitotic index (95% CI 1.228-4.079); p53 (95% CI 1.307-4.065); and invasion into the cavernous sinus (95% CI 3.842–7.502) predicted SPA progression after surgical resection. Our study suggested that specific cell-cycle regulators were associated with SPA progression.
A prospective study evaluating the relationship between fatigue and patient satisfaction in advanced cancer
Authors: R. D. Levin, M. Daehler, C. G. Lis, D. Gupta, T. Wodek, J. F. Grutsch, J. Granick, S. Williams, D. L. Citrin, R. Neelam
Journal: Journal of Clinical Oncology (2006)

16025 Background: Fatigue is the most common and disabling symptoms experienced by cancer patients. No study has prospectively quantified the relationship between fatigue and patient satisfaction (PS) in advanced cancer. We therefore assessed this relationship before the start of chemotherapy and at 3 and 6 months after treatment at our integrative cancer treatment center. Methods: 294 cancer patients treated at Cancer Treatment Centers of America between 04/01 and 11/04. Of 954 patients at baseline, only 294 were available for follow-up at 6 months. Fatigue was measured using the EORTC QLQ-C30 3-item fatigue subscale. Scores ranged from 0–100, higher scores indicating more fatigue. PS was measured using Ferrans &amp; Powers Quality of Life Index (QLI). Scores ranged from 0–30, higher scores indicating better QoL. The mean fatigue scores were compared using ANOVA across the 3 time periods at baseline, 3 and 6 months. The relationship between fatigue and QLI was evaluated using multiple linear regression at all 3 time points. Results: Of 294 patients, 106 were males and 188 females. 91 had breast ca, 52 colorectal, 43 lung, 25 pancreas, 13 prostate, and 70 had other cancers. 112 were newly diagnosed and 182 had received prior treatment elsewhere. The mean fatigue scores at baseline, 3 and 6 months were 43.6, 37.3, and 41.8 respectively; the scores at baseline and 3 months were significantly different (p = .009). At baseline, after controlling for age, gender, prior treatment history, and tumor stage at diagnosis, every 10 unit increase in fatigue was significantly associated with 1.3 units decrease in QLI health subscale. Similarly at 3 and 6 months after treatment, every 10 unit increase in fatigue was significantly associated with 1.2 and 1.4 units decrease in QLI health subscale. Conclusions: In our study, we found that fatigue is a strong correlate of PS independent of the effects of age, gender, prior treatment history and tumor stage at diagnosis during the first 6 months of treatment. Interestingly, fatigue showed a significant improvement after 3 months of treatment and returned back to baseline levels at 6 months. This finding needs to be investigated further to evaluate the impact of integrative cancer care services on PS. No significant financial relationships to disclose.
Child vs Adult Onset of Attention-Deficit/Hyperactivity Disorder—Reply
Authors: Louise Arseneault, Jessica Agnew-Blais, Terrie E. Moffitt
Journal: JAMA Psychiatry (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
HLA-A2 and immune checkpoints inhibitors in advanced non-small cell lung cancer (NSCLC) patients
Authors: L. Mezquita, M. Charrier, J. Lahmar, J. Remon, M.V. Bluthgen, F. Facchinetti, D. Planchard, A. Gazzah, L. Dupraz, J. Adam, N. Chaput, B. Besse
Journal: Annals of Oncology (2016)
Axitinib in recurrent or metastatic nasopharyngeal carcinoma (NPC): final result of a phase 2 clinical trial with pharmacokinetic (PK) correlation
Authors: E.P. Hui, B.B. Ma, F. Mo, M.K. Kam, S.L. Chan, H.H. Loong, R. Ho, S.F. Leung, A.D. King, K. Wang, A. Ahuja, C.M. Chan, C.W. Hui, C.H. Wong, A.T.C. Chan
Journal: Annals of Oncology (2016)
Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves
Authors: Anthony P. Carnicelli, Raffaele De Caterina, Jonathan L. Halperin, Giulia Renda, Christian T. Ruff, Marco Trevisan, Francesco Nordio, Michele F. Mercuri, Elliott Antman, Robert P. Giugliano
Journal: Circulation (2017)
Fibroblast growth factor receptor 3 (FGFR3) mutant muscle invasive bladder cancers (MIBC) are associated with low immune infiltrates
Authors: E. Kilgour, H. Angell, N.R. Smith, M. Ahdesmaki, J.C. Barrett, E.A. Harrington, C. Hurst, M.A. Knowles
Journal: Annals of Oncology (2016)
Structural and Functional Characterization of Fucoidan and Its Procoagulant Effect in An Ex Vivo Model of Factor VIII-Inhibited Guinea Pigs
Authors: Michael Dockal, Werner Hoellriegl, Zhenqing Zhang, Susanne Till, Sabine Knappe, Michael Palige, Alexandra Schiviz, Hartmut J. Ehrlich, Christina Szabo, Eva-Maria Muchitsch, Friedrich Scheiflinger
Journal: Blood (2011)
Histone Acetylation Mediated by Brd1 Is Crucial for Cd8 Gene Activation during Early Thymocyte Development
Authors: Yuta Mishima, Changshan Wang, Satoru Miyagi, Atsunori Saraya, Hiroyuki Hosokawa, Naoto Yamaguchi, Toshinori Nakayama, Haruhiko Koseki, Ichiro Taniuchi, Atsushi Iwama
Journal: Blood (2014)
Comparison of High-Dose Cyclophosphamide and Growth Factor with Growth Factor Alone for Mobilization of Stem Cells for Transplantation in Patients with Multiple Myeloma.
Authors: Morie Abraham Gertz, Shaji Kumar, Martha Lacy, Angela Dispenzieri, Suzanne Hayman, Francis Buadi, David Dingli, Dennis Gastineau, Jeffery Winters, Mark Litzow
Journal: Blood (2008)